The global Antibiotic Resistance Market size is expected to reach USD 12.48 billion by 2030, registering a CAGR of 5.27% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rise in the number of antibiotic-resistant infections due to misuse or overuse of antibiotics is a major factor attributing to market growth. Moreover, the increasing patient base across the globe and high costs associated with the treatment of diseases is anticipated to boost the market growth over the forecast period.

The prevalence of gram-negative infections is increasing at an alarming rate. These infections have lesser treatment options available in the market. The high unmet needs result in high demand for new therapies and, therefore, small and medium-sized pharmaceutical companies are actively involved in the development of novel treatment options. Moreover, the government and other organizations are also aiding research activities to drive the development of innovative therapies.

Multiple mid-level biotechnology companies have entered the arena with targeted therapies for antibiotic-resistant infections. Various manufacturers are developing therapies, especially for drug-resistant infections, that target a smaller population subset.

The U.S. government in alliance with BARDA is supporting several companies to boost the development of new therapies for antibiotic-resistant diseases. BARDA has also been associated with pharmaceutical companies such as GSK; Tetraphase; Basilea; Astra Zeneca; and many more. Many countries and international organizations have formed dedicated groups or alliances to monitor and study the pattern of drug-resistant infections.

For instance, the WHO has introduced the Global Antimicrobial Resistance Surveillance System (GLASS) to monitor antibiotic-resistant infections at a global level. Similarly, the Public Health Agency of Canada has introduced the Canadian Antimicrobial Resistance Surveillance System (CARSS) to study drug-resistant infections pattern at the country level.

However, according to a review published by WHO in March 2023, the antibiotics pipeline activities are limited, with only 12 new antibiotics being approved between 2017 and 2021. The review further stated that there are only 27 new candidates under development, out of which only 6 are considered “innovative” enough to be capable of overcoming antibiotic resistance as defined by WHO.

Related Press Release@ Antibiotic Resistance Market Report

Antibiotic Resistance Market Report Highlights

• In 2023, cUTI accounted for the largest market share and is anticipated to maintain its dominance in the global market in the coming years
• Combination drugs are expected to grow at the fastest CAGR over the forecast period
• North America dominated the antibiotic resistance industry in 2023. The target goals set by the U.S. national action plan in response to the significant burden of resistant gram-positive and negative infections is the key factor driving the market
• Asia Pacific is set to witness the fastest growth over the forecast period due to excessive consumption of antibiotics, advancements in technology, and growing awareness about antibiotic resistance testing, treatment, & management of the same.

Antibiotic Resistance Market Report Scope

Request For A Free Consultation @ https://www.grandviewresearch.com/request-free-consultation/5467/rfc

Antibiotic Resistance Market Segmentation

Grand View Research has segmented the global antibiotic resistance market based on disease, pathogen, drug class, mechanism of action, distribution channel, and region:

Antibiotic Resistance Disease Outlook (Revenue, USD Million, 2018 - 2030)

• cUTI (Complicated Urinary Tract Infections)
• CDI (Clostridioides difficile Infection)
• ABSSSI (Acute bacterial skin and skin structure infections)
• HABP (Hospital-acquired bacterial pneumonia)
• CABP (Community-acquired pneumonia)
• cIAI (Complicated intra-abdominal infection)
• BSI (Bloodstream infection)

Antibiotic Resistance Pathogen Outlook (Revenue, USD Million, 2018 - 2030)

• E. coli
• K. pneumoniae
• P. aeruginosa
• S. aureus
• A. baumannii
• S. pneumoniae
• H. influenzae
• C. difficile
• E. faecium

Antibiotic Resistance Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• Oxazolidinones
• Lipoglycopeptides
• Tetracyclines
• Combination therapies
• Cephalosporins
• Others

Antibiotic Resistance Mechanism of Action Outlook (Revenue, USD Million, 2018 - 2030)

• Protein Synthesis Inhibitors
• Cell Wall Synthesis Inhibitors
• RNA Synthesis Inhibitors
• DNA Synthesis Inhibitors
• Others

Antibiotic Resistance Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Antibiotic Resistance Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• China
• Japan
• India
• Australia
• Thailand
• South Korea
• Latin America
• Brazil
• Mexico
• Argentina
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait